Advertisement
News
Advertisement

Hernia: Covidien's Biologic Mesh Product Hits a Wall

Fri, 03/08/2013 - 11:23am
Mass Device

Covidien CFO Charles Dockendorff says there's not much room for growth in biologic tissue mesh for hernia repair, a product the company acquired in 2008.

Covidien logo

Covidien's (NYSE:COV) biologic hernia mesh product has hit a "brick wall," according to CFO Charles Dockendorff, but does that mean the company is looking to move on from the product it dropped more than $80 million to acquire?

Dockendorff, responding to a question from CitiGroup analyst Matthew Dodds at the investment bank's recent investor's conference, sounded downbeat about the fate of the product compared to the company's synthetic mesh.

Topics

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading